Mar 06, 2023 / 10:00PM GMT
Operator
Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call. (Operator Instructions)
I would now like to hand the call over to SVP Investor Relations, Marek Ciszewski. Please go ahead.
Marek Ciszewski - Coherus BioSciences, Inc. - SVP of IR
Thank you, Latif, and good afternoon, everyone, and thank you for joining us. We issued a press release earlier today announcing our financial results for the fourth quarter of 2022. This release can be found on the Coherus Biosciences website and is also attached to our Form 8-K. Today's call includes forward-looking statements regarding Coherus' current expectations about future events. These statements include, but are not limited to, our ability to gain approval for multiple new products and launched them, the ability of the FDA to complete required inspections in China for our BLA for toripalimab, timing of the end of our decline in revenues and timing of our ability to gain market share for any of our approved products; expectations about revenue
Q4 2022 Coherus BioSciences Inc Earnings Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers